Neurokinin receptor antagonism: a patent review (2014-present)

References

• Muñoz M, Coveñas R. Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids. 2014;46:1727–1750.
   PubMed Web of Science ®Google Scholar
• Ebner K, Sartori SB, Singewald, et al. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des. 2009;15:1647–1674.
   PubMed Web of Science ®Google Scholar
• Steinhoff MS, von Mentzer B, Geppetti P, et al. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev. 2014;94:265–301.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Coveñas R, Substance P. In: Substance P. Huhtaniemi I, Martini L, editors. Encyclopedia of endocrine diseases. Second ed. Vol. 1. Oxford: Academic Press; 2019. p. 571–578.
   Google Scholar
• Coveñas R, Martín F, Belda M, et al. Mapping of neurokinin-like immunoreactivity in the human brainstem. BMC Neurosci. 2003;4:3.
   PubMed Web of Science ®Google Scholar
• Duque E, Mangas A, Salinas P, et al. Mapping of alpha-neo-endorphin- and neurokinin B-immunoreactivity in the human brainstem. Brain Struct Funct. 2013;218:131–149.
   PubMed Web of Science ®Google Scholar
• Pennefather JN, Lecci A, Candenas ML, et al. Tachykinins and tachykinin receptors: a growing family. Life Sci. 2004;74:1445–1463.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Rosso M, Coveñas R. Neurokinin-1 receptor. In: Choi S, editor. Encyclopedia of signaling molecules. Cham: Springer; 2018. p. 3437–3445.
   Google Scholar
• Robinson P, Garza A, Moore J, et al. Substance P is required for the pathogenesis of EMCV infection in mice. Int J Clin Exp Med. 2009;2:76–86.
   PubMed Web of Science ®Google Scholar
• Li W, Fotinos A, Wu Q, et al. N-acetyl-L-tryptophan delays disease onset and extends survival in an amyotrophic lateral sclerosis transgenic mouse model. Neurobiol Dis. 2015;80:93–103.
   PubMed Web of Science ®Google Scholar
• Corrigan F, Vink R, Turner RJ. Inflammation in acute CNS injury: a focus on the role of substance P. Br J Pharmacol. 2016;173:703–715.
   PubMed Web of Science ®Google Scholar
• Coveñas R, Mangas A, Narváez JA. Introduction to neuropeptides. In: Coveñas R, Mangas A, Narváez JA, editors. Focus on neuropeptide research. Trivandrum: Transworld Research Network; 2007. p. 1–26.
   Google Scholar
• Onaga T. Tachykinin: recent developments and novel roles in health and disease. BioMol Concepts. 2014;5:225–243.
   PubMedGoogle Scholar
• Hökfelt T, Broberger C, Xu Z-Q, et al. Neuropeptides: an overview. Neuropharmacology. 2000;39:1337–1356.
   PubMed Web of Science ®Google Scholar
• Ständer S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5:e10968.
   PubMed Web of Science ®Google Scholar
• Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998;281:1640–1645.
   PubMed Web of Science ®Google Scholar
• Wang X, Douglas SD, Lai JP, et al. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. J Neuroimmune Pharmacol. 2007;2:42–48.
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012;13:1020–1024.
   PubMed Web of Science ®Google Scholar
• Rost K, Fleischer F, Nieber K. Neurokinin-1 receptor antagonists: between hope and disappointment. Med Monatsschr Pharm. 2006;29:200–205.
   PubMedGoogle Scholar
• Saito H, Yoshizawa H, Yoshimori K, et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-bind, placebo-controlled phase 3 trial. Ann Oncol. 2013;24:1067–1073.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Coveñas R. Safety of neurokinin-1 receptor antagonists. Expert Opin Drug Saf. 2013;12:673–685.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Crespo JC, Crespo JP, et al. Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: a case report. Mol Clin Oncol. 2019;11:50–54.
   PubMed Web of Science ®Google Scholar
• Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids. 2006;31:251–272.
   PubMed Web of Science ®Google Scholar
• Aziz F. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting. Ann Palliat Med. 2012;1:130–136.
   PubMedGoogle Scholar
• Heron Therapeutics Inc. Method of administering emulsion formulations of an NK- 1 receptor antagonist. WO2019152430. 2019.
   Google Scholar
• Heron Therapeutics Inc. Emulsion formulations of an NK-1 receptor antagonists and uses thereof. US2019000762. 2019.
   Google Scholar
• Opko Health Inc. Intravenous formulations of neurokinin-1 antagonists. US2016024092. 2016.
   Google Scholar
• Heron Therapeutics Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester. WO2014093907. 2014.
   Google Scholar
• Pharmathen SA Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof. US2015165045. 2015.
   Google Scholar
• Tibet Haisco Pharmaceutical Group Co. Ltd. Medicinal composition for treating emesis. CN103520725. 2014.
   Google Scholar
• XW Laboratories Inc. Compounds as neurokinin-1 receptor antagonists and uses thereof. WO2020020189. 2020.
   Google Scholar
• Chang SE, Han SS, Jung HJ, et al. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol. 2007;156:1272–1277.
   PubMed Web of Science ®Google Scholar
• Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat a variety of pruritic conditions. WO2018005695. 2018.
   Google Scholar
• Leo Pharma AS. Novel neurokinin 1 receptor antagonist compounds II. WO2015024203. 2015.
   Google Scholar
• Leo Pharma AS. Novel neurokinin 1 receptor antagonist compounds. US2015018345. 2015.
   Google Scholar
• Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat chronic pruritus. WO2020023898. 2020.
   Google Scholar
• Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat chronic pruritus associated with atopic dermatitis. WO2020023879. 2020.
   Google Scholar
• Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus. US10617671. 2020.
   Google Scholar
• Menlo Therapeutics Inc. Use of NK-1 receptor antagonists in pruritus. US2020054604. 2020.
   Google Scholar
• The Regents of the University of California. Itch treatment using a combination of neurokinin-1, gastrin releasing peptide, and glutamate receptor antagonists. WO2014113564. 2014.
   Google Scholar
• Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat pruritus. WO2020023873 (2020).
   Google Scholar
• Menlo Therapeutics Inc. Use of serlopitant as NK-1 receptor antagonist in pruritus. WO2014209962. 2014.
   Google Scholar
• Arola OJ, Saraste A, Pulkki, et al. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000;60:1789–1792.
   PubMed Web of Science ®Google Scholar
• Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992;19:670–686.
   PubMed Web of Science ®Google Scholar
• Goorin AM, Borow KM, Goldman A, et al. Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children. Cancer. 1981;47:2810–2816.
   PubMed Web of Science ®Google Scholar
• Robinson P, Kasembeli M, Bharadwaj U, et al. Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance. Biomed Res Int. 2016;2016:1959270.
   PubMed Web of Science ®Google Scholar
• Wake Forest University Health Sciences. Methods and compositions for treating anthracycline-induced cardiomyopathy using neurokinin-1 receptor antagonists. WO2015138186. 2015.
   Google Scholar
• Plus Vitech SL. Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract. WO2016012594. 2016.
   Google Scholar
• Linnane Pharma AB Novel therapy. WO2018007920. 2018.
   Google Scholar
• Menlo Therapeutics Inc. Use of neurokinin-1 antagonists as antitussives. WO2018136554. 2018.
   Google Scholar
• Nerre Therapeutics Ltd. Overpitant for the treatment of chronic cough. EP3377064. 2018.
   Google Scholar
• Amorepacific Corporation. External composition comprising a melanogenesis inhibitor. KR20140107820. 2014.
   Google Scholar
• Muñoz M, Rosso M, Coveñas R. A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem. 2010;17:504–516.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Martínez-Armesto J, Coveñas R. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011. Expert Opin Ther Patents. 2012;22:735–746.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Berger M, Rosso M, et al. Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts. Int J Oncol. 2014;44:137–146.
   PubMed Web of Science ®Google Scholar
• Oncoprevent Gmbh. Neurokinin-1 receptor antagonists for use in a method of prevention of cancer. WO2015101596. 2015.
   Google Scholar
• NK 1 IP Ltd. Use of non-peptidic NK1 receptor antagonists for the production of apoptosis in tumour cells. US2020054620. 2020.
   Google Scholar
• Consejo Superior Investigación. Antagonists of NK1 receptors derived from carbohydrates, production method and medical use. US2019092802. 2019.
   Google Scholar
• Ospedale San Raffaele Srl. NK-1 antagonists for use in the treatment of ocular pain. WO2019162519. 2019.
   Google Scholar
• Ferrari Giulio. Novel method. US2014128395. 2014.
   Google Scholar
• Opko Health Inc. NK-1 antagonists. US2018215729. 2018.
   Google Scholar
• Vanda Pharmaceuticals Inc. Method of treatment with tradipitant. US2020030307. 2020.
   Google Scholar
• Univ Henan Normal. Non-peptide tachykinin receptor antagonist preparation method. CN106631972. 2017.
   Google Scholar
• Ogeda SA NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat. US10624890. 2020.
   Google Scholar
• Ogeda SA N-acyl-(3-substituted)-(8-substituted)-5, 6-dihydro-[1, 2, 4] triazolo [4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders. JP20180062649. 2018.
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrrolidine derivatives. RU2012127272. 2014.
   Google Scholar
• Ogeda SA Chiral N-acyl-5,6,7-(8-substituted) tetrahydro [1,2,4] triazolo [4,3- a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof. EA029340. 2018.
   Google Scholar
• Biran J, Golan M, Mizrahi N, et al. Direct regulation of gonadotropin release by neurokinin B in tilapia (Oreochromis niloticus). Endocrinology. 2014;155:4831–4842.
   PubMed Web of Science ®Google Scholar
• Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Antagonists of fish reproduction. US2019169256. 2019.
   Google Scholar
• Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Antagonists of neurokinin B in fish reproduction. WO2016009439. 2016.
   Google Scholar
• Emory University. Methods of managing conditioned fear with neurokinin receptor Antagonists. US201916369594. 2019.
   Google Scholar
• Williams JB, Pang D, Delgado B, et al. A model of gene-environment interaction reveals altered mammary gland gene expression and increased tumor growth following social isolation. Cancer Prev Res. 2009;2:850–861.
   PubMed Web of Science ®Google Scholar
• Chou KL, Liang K, Sareen J. The association between social isolation and DSM-IV mood, anxiety, and substance use disorders: wave 2 of the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry. 2011;72:1468–1476.
   PubMed Web of Science ®Google Scholar
• Huang H, Wang L, Cao M, et al. Isolation housing exacerbates Alzheimer’s disease-like pathophysiology in aged APP/PS1 mice. Int J Neuropsychopharmacol. 2015;18:pyu116.
   PubMed Web of Science ®Google Scholar
• California Institute of Technology. Neurokinin antagonists and uses thereof. WO2019090001. 2019.
   Google Scholar
• The University Court of the University of Edinburgh. Neurokinin B antagonist for use in inhibiting follicle development. WO2016135495. 2016.
   Google Scholar
• Archer DF, Sturdee DW, Baber R, et al. Menopausal hot flushes and night sweats: where are we now? Climacteric. 2011;14:515–528.
   PubMed Web of Science ®Google Scholar
• IMP Innovations Ltd. Method for treating or preventing hot flushes. WO2015033163. 2015.
   Google Scholar
• Nerre Therapeutics Limited. Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases. WO2016184829. 2016.
   Google Scholar
• Kandy Therapeutics Ltd. Novel pharmaceutical formulation comprising dual NK- 1/NK-3 receptor antagonists. WO2019175253. 2019.
   Google Scholar
• Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov. 2012;11:462–478.
   PubMed Web of Science ®Google Scholar
• Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance P (neurokinin 1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006;59:216–223.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Parrilla J, Rosso M, et al. Antipruritic vs. antitumour action of aprepitant: a question of dose. Acta Derm Venereol. 2019;99:620–621.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Coveñas R. Involvement of substance P and the NK-1 receptor in cancer progression. Peptides. 2013;48:1–9.
   PubMed Web of Science ®Google Scholar